Logo image of BGLC

BIONEXUS GENE LAB CORP (BGLC) Stock Fundamental Analysis

NASDAQ:BGLC - Nasdaq - US0906282076 - Common Stock - Currency: USD

0.3513  +0.01 (+2.72%)

Fundamental Rating

3

Taking everything into account, BGLC scores 3 out of 10 in our fundamental rating. BGLC was compared to 49 industry peers in the Trading Companies & Distributors industry. No worries on liquidiy or solvency for BGLC as it has an excellent financial health rating, but there are worries on the profitability. BGLC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

BGLC had negative earnings in the past year.
In the past year BGLC has reported a negative cash flow from operations.
In multiple years BGLC reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: BGLC reported negative operating cash flow in multiple years.
BGLC Yearly Net Income VS EBIT VS OCF VS FCFBGLC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 0 1M -1M -2M

1.2 Ratios

BGLC has a worse Return On Assets (-8.57%) than 95.83% of its industry peers.
BGLC has a Return On Equity of -10.04%. This is amonst the worse of the industry: BGLC underperforms 87.50% of its industry peers.
Industry RankSector Rank
ROA -8.57%
ROE -10.04%
ROIC N/A
ROA(3y)-6.45%
ROA(5y)-5.78%
ROE(3y)-7.39%
ROE(5y)-5.63%
ROIC(3y)N/A
ROIC(5y)N/A
BGLC Yearly ROA, ROE, ROICBGLC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 -50 -100

1.3 Margins

The Gross Margin of BGLC (13.47%) is worse than 95.83% of its industry peers.
In the last couple of years the Gross Margin of BGLC has remained more or less at the same level.
BGLC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 13.47%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.41%
GM growth 5Y-0.97%
BGLC Yearly Profit, Operating, Gross MarginsBGLC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 0 50 -50 -100 -150 -200

More info and screens

8

2. Health

2.1 Basic Checks

BGLC does not have a ROIC to compare to the WACC, probably because it is not profitable.
BGLC has more shares outstanding than it did 1 year ago.
BGLC has more shares outstanding than it did 5 years ago.
BGLC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BGLC Yearly Shares OutstandingBGLC Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M
BGLC Yearly Total Debt VS Total AssetsBGLC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

2.2 Solvency

An Altman-Z score of 3.13 indicates that BGLC is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.13, BGLC is in the better half of the industry, outperforming 60.42% of the companies in the same industry.
BGLC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.13
ROIC/WACCN/A
WACC10.84%
BGLC Yearly LT Debt VS Equity VS FCFBGLC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 2M 4M 6M 8M

2.3 Liquidity

A Current Ratio of 4.98 indicates that BGLC has no problem at all paying its short term obligations.
BGLC's Current ratio of 4.98 is amongst the best of the industry. BGLC outperforms 100.00% of its industry peers.
A Quick Ratio of 3.99 indicates that BGLC has no problem at all paying its short term obligations.
BGLC has a better Quick ratio (3.99) than 97.92% of its industry peers.
Industry RankSector Rank
Current Ratio 4.98
Quick Ratio 3.99
BGLC Yearly Current Assets VS Current LiabilitesBGLC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M

More info and screens

3

3. Growth

3.1 Past

BGLC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 77.85%, which is quite impressive.
BGLC shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -10.48%.
Measured over the past years, BGLC shows a very strong growth in Revenue. The Revenue has been growing by 115.55% on average per year.
EPS 1Y (TTM)77.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.92%
Revenue 1Y (TTM)-10.48%
Revenue growth 3Y-4.98%
Revenue growth 5Y115.55%
Sales Q2Q%3%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BGLC Yearly Revenue VS EstimatesBGLC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
BGLC Yearly EPS VS EstimatesBGLC Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BGLC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BGLC Price Earnings VS Forward Price EarningsBGLC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BGLC Per share dataBGLC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BGLC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIONEXUS GENE LAB CORP

NASDAQ:BGLC (2/21/2025, 8:03:18 PM)

0.3513

+0.01 (+2.72%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryTrading Companies & Distributors
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.99%
Inst Owner Change-83.67%
Ins Owners32.59%
Ins Owner Change0%
Market Cap6.31M
AnalystsN/A
Price TargetN/A
Short Float %3.1%
Short Ratio0.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.68
P/FCF N/A
P/OCF N/A
P/B 0.67
P/tB 0.67
EV/EBITDA N/A
EPS(TTM)-0.04
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)-0.14
OCFYN/A
SpS0.52
BVpS0.52
TBVpS0.52
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.57%
ROE -10.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 13.47%
FCFM N/A
ROA(3y)-6.45%
ROA(5y)-5.78%
ROE(3y)-7.39%
ROE(5y)-5.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.41%
GM growth 5Y-0.97%
F-Score2
Asset Turnover0.84
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 236.42%
Cap/Sales 2.42%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.98
Quick Ratio 3.99
Altman-Z 3.13
F-Score2
WACC10.84%
ROIC/WACCN/A
Cap/Depr(3y)78.34%
Cap/Depr(5y)145.34%
Cap/Sales(3y)0.66%
Cap/Sales(5y)2.67%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)77.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.92%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-10.48%
Revenue growth 3Y-4.98%
Revenue growth 5Y115.55%
Sales Q2Q%3%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y67.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-619.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-541.16%
OCF growth 3YN/A
OCF growth 5YN/A